Yazar "Kalincik, Tomas" için listeleme
-
Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
Kalincik, Tomas; Jokubaitis, Vilija; Spelman, Tim; Horakova, Dana; Havrdova, Eva; Trojano, Maria; Barnett, Michael (Sage Publications Ltd, 2018)Objective: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon , fingolimod or natalizumab. Methods: We identified all patients with relapse-onset multiple sclerosis, ... -
Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS
Spelman, Tim; Kalincik, Tomas; Jokubaitis, Vilija; Zhang, Annie; Pellegrini, Fabio; Wiendl, Heinz; Lechner-Scott, Jeannette (Lippincott Williams & Wilkins, 2016)Background: We compared efficacy and treatment persistence in treatment-naive patients with relapsing-remitting multiple sclerosis (RRMS) initiating natalizumab compared with interferon-beta (IFN-beta)/glatiramer acetate ... -
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Kalincik, Tomas; Havrdova, Eva Kubala; Horakova, Dana; Izquierdo, Guillermo; Prat, Alexandre; Girard, Marc; Turkoglu, Recai (Bmj Publishing Group, 2019)Objective Oral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and disability is needed. Methods We identified all patients with ... -
Defining reliable disability outcomes in multiple sclerosis
Kalincik, Tomas; Cutter, Gary; Spelman, Tim; Jokubaitis, Vilija; Havrdova, Eva; Horakova, Dana; Ramo, Cristina (Oxford Univ Press, 2015)Prevention of irreversible disability is currently the most important goal of disease modifying therapy for multiple sclerosis. The disability outcomes used in most clinical trials rely on progression of Expanded Disability ... -
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study
Nguyen, Ai-Lan; Havrdova, Eva Kubala; Horakova, Dana; Izquierdo, Guillermo; Kalincik, Tomas; van der Walt, Anneke; Granella, Franco (Elsevier Sci Ltd, 2019)Background: Exposure to disease-modifying therapy (DMT) during early pregnancy in women with relapsing-remitting MS (RAMS) may be increasing. Objective: To retrospectively determine incidence of pregnancy, DMT exposure and ... -
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice
Spelman, Tim; Meyniel, Claire; Ignacio Rojas, Juan; Lugaresi, Alessandra; Izquierdo, Guillermo; Grand'Maison, Francois; Kalincik, Tomas (Sage Publications Ltd, 2017)Background: Characteristics at clinically isolated syndrome (CIS) examination assist in identification of patient at highest risk of early second attack and could benefit the most from early disease-modifying drugs (DMDs). ... -
Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Kalincik, Tomas; Horakova, Dana; Spelman, Tim; Jokubaitis, Vilija; Trojano, Maria; Lugaresi, Alessandra; Bergamaschi, Roberto (Wiley, 2015)ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly ... -
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
Kalincik, Tomas; Manouchehrinia, Ali; Sobisek, Lukas; Jokubaitis, Vilija; Spelman, Tim; Horakova, Dana; Iuliano, Gerardo (Oxford Univ Press, 2017)Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response varies greatly among patients. Comprehensive predictive models of individual treatment response ... -
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
Kalincik, Tomas; Brown, J. William L.; Robertson, Neil; Willis, Mark; Scolding, Neil; Rice, Claire M.; Sola, Patrizia (Elsevier Science Inc, 2017)Background Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies ...
